| Diabetes Mellitus, Non-Insulin-Dependent
Ozempic vs Soliqua
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Ozempic vs Soliqua 100/33 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSoliqua 100/33 has a higher rate of injection site reactions vs Ozempic based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Soliqua 100/33 but not Ozempic, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ozempic
Soliqua 100/33
At A Glance
SC injection
Once weekly
GLP-1 receptor agonist
SC injection
Once daily
Basal insulin + GLP-1 receptor agonist
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; escalate to 1 mg then 2 mg based on glycemic control (max 2 mg once weekly).
Chronic Kidney Diseases Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; maintenance dose is 1 mg once weekly.
Diabetes Mellitus, Non-Insulin-Dependent 15 units SC once daily for patients naive to basal insulin or GLP-1 receptor agonist, on a GLP-1 receptor agonist, or on <30 units basal insulin daily; 30 units SC once daily for patients on 30-60 units basal insulin daily; titrate by 2-4 units weekly; max 60 units (60 units insulin glargine/20 mcg lixisenatide) daily; inject within 1 hour prior to first meal of the day.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
- Serious hypersensitivity reaction to semaglutide or any excipient in Ozempic
- Hypoglycemia episodes
- Serious hypersensitivity to insulin glargine, lixisenatide, or any excipient in SOLIQUA 100/33
Adverse Reactions
Most common (>=5%) Nausea, vomiting, diarrhea, abdominal pain, constipation
Serious Risk of thyroid C-cell tumors, acute pancreatitis, diabetic retinopathy complications, hypoglycemia with insulin secretagogues or insulin, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration
Postmarketing Ileus, intestinal obstruction, severe constipation, fecal impaction, anaphylaxis, angioedema, rash, urticaria, cholecystitis, cholecystectomy, dysesthesia, headache, pulmonary aspiration, acute kidney injury, alopecia
Most common (>=5%) Nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, headache, hypoglycemia
Serious Anaphylaxis, serious hypersensitivity, acute pancreatitis, hypoglycemia, acute kidney injury due to volume depletion, hypokalemia, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Localized cutaneous amyloidosis (insulin glargine); acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, cholecystitis, cholelithiasis, dysgeusia, dysesthesia, pulmonary aspiration, acute renal failure, alopecia (lixisenatide)
Pharmacology
Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner, with a minor delay in gastric emptying; prolonged half-life is achieved through albumin binding, which reduces renal clearance and protects against metabolic degradation.
SOLIQUA 100/33 combines insulin glargine, a basal insulin analog that lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production, with lixisenatide, a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ozempic
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Soliqua 100/33
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (7/12) · Qty limit (11/12)
UnitedHealthcare
Ozempic
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
Soliqua 100/33
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Ozempic
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Soliqua 100/33
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Ozempic Savings Program - Covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Soliqua 100/33.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OzempicView full Ozempic profile
Soliqua 100/33View full Soliqua 100/33 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.